European Union - English - EMA (European Medicines Agency)

astellas pharma gmbh - tacrolimus - dermatitis, atopic - other dermatological preparations - treatment of moderate to severe atopic dermatitis in adults who are not adequately responsive to or are intolerant of conventional therapies such as topical corticosteroids. treatment of moderate to severe atopic dermatitis in children (2 years of age and above) who failed to respond adequately to conventional therapies such as topical corticosteroids.maintenance treatment of moderate to severe atopic dermatitis for the prevention of flares and the prolongation of flare-free intervals in patients experiencing a high frequency of disease exacerbations (i.e. occurring 4 or more times per year) who have had an initial response to a maximum of 6 weeks treatment of twice daily tacrolimus ointment (lesions cleared, almost cleared or mildly affected).

European Union - English - EMA (European Medicines Agency)

astellas pharma europe b.v. - tacrolimus - graft rejection - immunosuppressants - prophylaxis of transplant rejection in adult and paediatric, kidney, liver or heart allograft recipients.treatment of allograft rejection resistant to treatment with other immunosuppressive medicinal products in adult and paediatric patients.

European Union - English - EMA (European Medicines Agency)

astellas pharma europe bv - tacrolimus - graft rejection - immunosuppressants - prophylaxis of transplant rejection in adult kidney or liver allograft recipients.treatment of allograft rejection resistant to treatment with other immunosuppressive medicinal products in adult patients.

United Kingdom - English - MHRA (Medicines & Healthcare Products Regulatory Agency)

astellas pharma ltd - tacrolimus monohydrate - modified-release capsule - 500microgram

United Kingdom - English - MHRA (Medicines & Healthcare Products Regulatory Agency)

astellas pharma ltd - tacrolimus monohydrate - modified-release capsule - 1mg

United Kingdom - English - MHRA (Medicines & Healthcare Products Regulatory Agency)

astellas pharma ltd - tacrolimus monohydrate - modified-release capsule - 5mg

United Kingdom - English - MHRA (Medicines & Healthcare Products Regulatory Agency)

astellas pharma ltd - tacrolimus monohydrate - modified-release capsule - 3mg

European Union - English - EMA (European Medicines Agency)

astellas pharma europe b.v. - mirabegron - urinary bladder, overactive - urologicals - symptomatic treatment of urgency.increased micturition frequency and / or urgency incontinence as may occur in adult patients with overactive-bladder syndrome.

United Kingdom - English - MHRA (Medicines & Healthcare Products Regulatory Agency)

astellas pharma ltd - fidaxomicin - tablet - 200mg

European Union - English - EMA (European Medicines Agency)

astellas pharma europe b.v. - enzalutamide - prostatic neoplasms - endocrine therapy - xtandi is indicated for:the treatment of adult men with metastatic hormone-sensitive prostate cancer (mhspc) in combination with androgen deprivation therapy (see section 5.1).the treatment of adult men with high-risk non-metastatic castration-resistant prostate cancer (crpc) (see section 5.1).the treatment of adult men with metastatic crpc who are asymptomatic or mildly symptomatic after failure of androgen deprivation therapy in whom chemotherapy is not yet clinically indicated (see section 5.1).the treatment of adult men with metastatic crpc whose disease has progressed on or after docetaxel therapy.